ViiV Healthcare gets FDA breakthrough therapy status for HIV prevention drug cabotegravir

This article was originally published here

The status was based on efficacy and safety results from HPTN 083 phase IIb/III randomised, multicentre, double-blind and clinical trial. The study compared long-acting and injectable cabotegravir to

The post ViiV Healthcare gets FDA breakthrough therapy status for HIV prevention drug cabotegravir appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply